- Home
- MEIP vs GOVX Comparison
MEIP vs GOVX Comparison
Compare MEIP & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MEIP
- GOVX
- Stock Information
- Founded
- MEIP 2000
- GOVX 2001
- Country
- MEIP United States
- GOVX United States
- Employees
- MEIP N/A
- GOVX N/A
- Industry
- MEIP Biotechnology: Pharmaceutical Preparations
- GOVX Biotechnology: Pharmaceutical Preparations
- Sector
- MEIP Health Care
- GOVX Health Care
- Exchange
- MEIP Nasdaq
- GOVX Nasdaq
- Market Cap
- MEIP 13.3M
- GOVX 15.5M
- IPO Year
- MEIP 2003
- GOVX N/A
- Fundamental
- Price
- MEIP $2.53
- GOVX $0.96
- Analyst Decision
- MEIP Hold
- GOVX Strong Buy
- Analyst Count
- MEIP 1
- GOVX 5
- Target Price
- MEIP N/A
- GOVX $12.40
- AVG Volume (30 Days)
- MEIP 21.5K
- GOVX 1.6M
- Earning Date
- MEIP 05-13-2025
- GOVX 08-05-2025
- Dividend Yield
- MEIP N/A
- GOVX N/A
- EPS Growth
- MEIP N/A
- GOVX N/A
- EPS
- MEIP N/A
- GOVX N/A
- Revenue
- MEIP N/A
- GOVX $5,591,576.00
- Revenue This Year
- MEIP N/A
- GOVX N/A
- Revenue Next Year
- MEIP N/A
- GOVX N/A
- P/E Ratio
- MEIP N/A
- GOVX N/A
- Revenue Growth
- MEIP 33.76
- GOVX N/A
- 52 Week Low
- MEIP $1.46
- GOVX $0.73
- 52 Week High
- MEIP $4.10
- GOVX $11.18
- Technical
- Relative Strength Index (RSI)
- MEIP 78.43
- GOVX 46.22
- Support Level
- MEIP $2.21
- GOVX $0.85
- Resistance Level
- MEIP $2.95
- GOVX $1.39
- Average True Range (ATR)
- MEIP 0.15
- GOVX 0.15
- MACD
- MEIP 0.05
- GOVX -0.02
- Stochastic Oscillator
- MEIP 81.48
- GOVX 18.52
About MEIP MEI Pharma Inc.
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.